Skip to content

Vanderbilt Memory and Aging Project

Vanderbilt Memory and Aging Project

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05372159
Acronym
VMAP
Enrollment
1000
Registered
2022-05-12
Start date
2012-09-17
Completion date
2027-12-31
Last updated
2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aged, 80 and Over, Aging, Alzheimer Disease, Biomarkers, Brain, Case-Control Studies, Cognitive Dysfunction, Neuropsychological Tests

Keywords

Alzheimer's disease, biomarkers, brain MRI, cardiac MRI, mild cognitive impairment, vascular risk factors, longitudinal studies

Brief summary

This study will use an observational cohort to cross-sectionally and longitudinally relate vascular health to clinical, imaging, and biological markers of early Alzheimer's disease and cerebrovascular disease among aging adults. Adjusting for relevant clinical covariates, we will test the hypothesis that vascular health is associated with clinical, brain magnetic resonance imaging (MRI), neuropsychological, and cerebrospinal fluid markers of early cerebrovascular and Alzheimer's disease changes (i.e., prior to the onset of significant cognitive decline or dementia). Secondarily, we will examine medical and genetic factors that might mediate associations between vascular health and brain aging, such as inflammatory processes, insulin resistance, and genetic factors (e.g., APOE, a susceptibility risk factor for dementia). Findings will advance knowledge regarding the role that vascular health plays in brain aging.

Detailed description

As the population ages, Alzheimer's disease and dementia are becoming a public health crisis. In the initial cycle, the Vanderbilt Memory & Aging Project was established to examine cardiovascular function in relation to structural neuroimaging changes and cognition. The investigators tested whether associations were more prominent in clinically symptomatic individuals. The investigators successfully enrolled several hundred participants age 60 and older, data successfully supported multiple training grant opportunities (e.g., National Research Service Awards, Career Development Awards), and the investigators published numerous papers. The results suggest subclinical cardiovascular changes relate to worse cognition, white matter changes, and cerebral atrophy, especially in the hippocampus and other cortical regions primarily affected in Alzheimer's disease. Evidence to date supports the central hypothesis that well-established homeostatic mechanisms designed to protect cerebral blood supply become less effective with age, altering the integrity of cerebral hemodynamics, and lowering the threshold for neurodegenerative and cognitive changes. Interestingly, preliminary associations between subclinical cardiovascular integrity and cerebral hemodynamics are stronger among carriers of the apolipoprotein E ε4 (APOE-ε4) allele, an Alzheimer's disease genetic risk factor. Furthermore, findings are more prominent in cognitively unimpaired participants, suggesting subtle cardiac hemodynamic changes may act as an underrecognized precipitating contributor of neurodegeneration and corresponding cognitive decline, distinct from the exacerbating effects of overt cerebrovascular disease. In the next cycle, the investigators propose to better characterize underlying mechanisms linking early cardiac hemodynamic changes to abnormal brain aging in cognitively unimpaired participants, and test whether APOE-ε4 moderates the effect of vascular damage on brain health. The investigators will follow the existing cohort and supplement it with enrollment of several hundred cognitively unimpaired participants to increase statistical power for more comprehensive analyses. The new participants will complete serial longitudinal assessments with identical procedures plus lumbar puncture for cerebrospinal fluid acquisition. Innovative translational efforts leveraging sophisticated neuroimaging and molecular biomarkers are critical to better detect early, asymptomatic cardiac hemodynamic changes, which may be more influential in initiating downstream cerebrovascular and neurodegenerative processes than previously recognized.

Interventions

none, observational study

Sponsors

Vanderbilt University Medical Center
Lead SponsorOTHER
National Institute on Aging (NIA)
CollaboratorNIH
National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants recruited will include 1,000 adults age 50 and older. * After the eligibility visit, a small portion of participants (\~150) enrolling must meet diagnostic criteria for mild cognitive impairment according to a clinician diagnosis and/or medical records (i.e., participants must have mild memory or cognitive problems, but they must be free of any functional problems and not have Alzheimer's disease or another form of dementia). The remaining \~850 participants will be cognitively unimpaired adults age 50 and older. * Because the neuropsychological tests used to measure cognitive performance are validated on English-speaking populations, we require that English be the primary language of all participants.

Exclusion criteria

* No available reliable study partner * History of major psychiatric illness (e.g., schizophrenia, bipolar), neurological illness (e.g., stroke, epilepsy, multiple sclerosis, Parkinson's disease, dementia), or head injury with significant loss of consciousness. These

Design outcomes

Primary

MeasureTime frameDescription
White matter hyperintensities Volumebaseline to year fiveWhite matter lesion volume measured by FLAIR imaging modality
Grey Matter Volumebaseline to year fiveGrey matter volume measured by T1 imaging modality
Cerebral Blood Flowbaseline to year fiveResting cerebral blood flow to brain regions measured by T3 perfusion
Lacunar infarctsbaseline to year fiveNumber of lacunar infarcts measured by MRI
Small vessel microbleedsbaseline to year fivePresence and number of microbleeds measured by MRI
Left ventricular ejection fractionbaseline to year fiveLeft ventricular ejection fraction measured by echocardiogram
Cardiac outputbaseline to year fiveAmount of blood the heart pumps from each ventricle per minute, litres per minute (L/min). Measured by echocardiogram
Cardiac stroke volumebaseline to year fiveStroke volume measured by echocardiogram
Pulse Wave velocitybaseline to year fivepulse wave velocity measured by cardiac MRI
Cardiac Strainbaseline to year fiveGlobal longitudinal strain and global circumferential strain measured by cardiac MRI
Biological marker for Alzheimer's diseasebaseline to year fiveTau, amyloid, neurodegenerative levels measured in cerebrospinal fluid samples
Blood based biological marker for Alzheimer's diseasebaseline to year fiveTau, amyloid, neurodegenerative levels measured in blood samples
APOE Genotypebaseline to year fiveAPOE e4 allele status

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAngela Jefferson, PhD

Vanderbilt University Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026